News

Podcast

A Medical Home Visit Program’s Takeaways From COVID-19

The authors of a Commentary in the November 2020 issue of The American Journal of Managed Care describe the experience of reimagining how a home health program can deliver care amid the coronavirus disease 2019 pandemic.

The coronavirus disease 2019 (COVID-19) pandemic has required health care systems to overhaul their ways of delivering care to patients in order to keep patients, families, and clinicians safe. For medical home visit programs accustomed to visiting patients in person, this task has required creative use of new technologies and relied on regulatory flexibility to facilitate their work.

On this episode of Managed Care Cast, we’re talking with the authors of a Commentary article published in our November issue. The article, “Medical Home Visit Programs During COVID-19 State of Emergency,” describes the experience of reimagining how a home health program can deliver care amid the coronavirus disease 2019 pandemic.

The authors, from Northwell Staten Island University Hospital in Staten Island, New York, are Donna Seminara, MD; Anita Szerszen, MD; John R. Maese, MD; and Zeel Shah, MD.

Listen above or through one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Read more:

Medical Home Visit Programs During COVID-19 State of Emergency

Ensuring Access to Health Care by FQHCs as States Reopen Amid COVID-19

Could COVID-19 Become a Policy Tipping Point? A Q&A With Kavita K. Patel, MD, MS

Who Should We Treat: Elective Surgical Admissions or Patients With COVID-19?

Hands Down, COVID-19 Will Change Medical Practice

Crisis Into Opportunity: Can COVID-19 Help Set a Path to Improved Health Care Efficiency?

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Cesar Davila-Chapa, MD
Female doctor in coat with stethoscope on blue background - Pixel-Shot - stock.adobe.com
Krunal Patel, MD
Juan Carlos Martinez, MD
Rachel Dalthorp, MD
dr joseph alvarnas
dr jennifer green
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo